Drug
Giredestrant
Giredestrant: highest development phase Phase 2, developed by Roche. 2 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Roche
Trials
| Drug | Phase | Indication |
|---|---|---|
| Giredestrant NCT05896566 | Phase 2 | Breast Cancer |
| Giredestrant NCT04802759 | Phase 1/2 | Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer |
Latest
No recent events.
Follow Giredestrant on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.